Relay Therapeutics (RLAY) Cash from Investing Activities (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Cash from Investing Activities data on file, last reported at $32.9 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 22.52% year-over-year to $32.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $183.2 million (up 2102.79% YoY) and the FY2025 annual result came in at $192.8 million, up 569.29% from the prior year.
• Cash from Investing Activities retreated to $32.9 million in Q1 2026 per RLAY's latest filing, from $35.5 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $75.3 million in Q1 2023 and bottomed at -$146.9 million in Q4 2022.
• The 5-year median for Cash from Investing Activities is $39.7 million (2025), against an average of $14.9 million.
• The widest annual swing landed in 2024, when Cash from Investing Activities slumped 276.78%; it then surged 303.24% in 2025.
• Tracing RLAY's Cash from Investing Activities over 5 years: stood at -$146.9 million in 2022, then jumped by 140.61% to $59.7 million in 2023, then sank by 51.41% to $29.0 million in 2024, then advanced by 22.29% to $35.5 million in 2025, then fell by 7.22% to $32.9 million in 2026.
• Per Business Quant, the three latest RLAY Cash from Investing Activities figures stand at $32.9 million (Q1 2026), $35.5 million (Q4 2025), and $39.7 million (Q3 2025).

Peer Comparison